These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22691217)

  • 1. Clinical trial design in scleroderma: where are we and where do we go next?
    Chung L; Denton CP; Distler O; Furst DE; Khanna D; Merkel PA;
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S97-102. PubMed ID: 22691217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Trial Design Issues in Systemic Sclerosis: an Update.
    Gordon JK; Domsic RT
    Curr Rheumatol Rep; 2016 Jun; 18(6):38. PubMed ID: 27146381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials.
    Khanna D; Brown KK; Clements PJ; Elashoff R; Furst DE; Goldin J; Seibold JR; Silver RM; Tashkin DP; Wells AU
    Clin Exp Rheumatol; 2010; 28(2 Suppl 58):S55-62. PubMed ID: 20576216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a provisional core set of response measures for clinical trials of systemic sclerosis.
    Khanna D; Lovell DJ; Giannini E; Clements PJ; Merkel PA; Seibold JR; Matucci-Cerinic M; Denton CP; Mayes MD; Steen VD; Varga J; Furst DE;
    Ann Rheum Dis; 2008 May; 67(5):703-9. PubMed ID: 17893248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials.
    Humbert M; Singh M; Furst DE; Khanna D; Seibold JR
    Rheumatology (Oxford); 2017 Sep; 56(suppl_5):v33-v37. PubMed ID: 28992168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis.
    Gualtierotti R; Ingegnoli F; Two R; Meroni PL; Khanna D; Adorni G; Becciolini A; Ciavarella T; Marfia G; Murgo A; Scalone L; Ughi N; Zeni S;
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S55-60. PubMed ID: 26339890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis.
    White B; Bauer EA; Goldsmith LA; Hochberg MC; Katz LM; Korn JH; Lachenbruch PA; LeRoy EC; Mitrane MP; Paulus HE
    Arthritis Rheum; 1995 Mar; 38(3):351-60. PubMed ID: 7880189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Points to consider for skin ulcers in systemic sclerosis.
    Galluccio F; Allanore Y; Czirjak L; Furst DE; Khanna D; Matucci-Cerinic M
    Rheumatology (Oxford); 2017 Sep; 56(suppl_5):v67-v71. PubMed ID: 28992171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Points to consider for designing trials in systemic sclerosis patients with arthritic involvement.
    Clements P; Allanore Y; Furst DE; Khanna D
    Rheumatology (Oxford); 2017 Sep; 56(suppl_5):v23-v26. PubMed ID: 28992165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).
    Kowal-Bielecka O; Landewé R; Avouac J; Chwiesko S; Miniati I; Czirjak L; Clements P; Denton C; Farge D; Fligelstone K; Földvari I; Furst DE; Müller-Ladner U; Seibold J; Silver RM; Takehara K; Toth BG; Tyndall A; Valentini G; van den Hoogen F; Wigley F; Zulian F; Matucci-Cerinic M;
    Ann Rheum Dis; 2009 May; 68(5):620-8. PubMed ID: 19147617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment.
    Villela R; Yuen SY; Pope JE; Baron M;
    Arthritis Rheum; 2008 May; 59(5):706-13. PubMed ID: 18438906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospects for improving outcomes in systemic sclerosis-related pulmonary hypertension.
    Thakkar V; Nikpour M; Stevens WM; Proudman SM
    Intern Med J; 2015 Mar; 45(3):248-54. PubMed ID: 25735576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome measures in rheumatologic clinical trials and systemic sclerosis.
    Furst DE
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v29-30. PubMed ID: 18784136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group registry.
    Khimdas S; Harding S; Bonner A; Zummer B; Baron M; Pope J;
    Arthritis Care Res (Hoboken); 2011 Jan; 63(1):142-9. PubMed ID: 20740608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome measures in pulmonary arterial hypertension associated with systemic sclerosis.
    Kowal-Bielecka O; Delcroix M; Vonk-Noordegraaf A; Hoeper MM; Naeije R
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v39-41. PubMed ID: 18784140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interstitial lung disease points to consider for clinical trials in systemic sclerosis.
    Khanna D; Seibold J; Goldin J; Tashkin DP; Furst DE; Wells A
    Rheumatology (Oxford); 2017 Sep; 56(suppl_5):v27-v32. PubMed ID: 28992174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A standardized core set for systemic sclerosis clinical trials. First step in development of combined response index.
    Khanna D
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5(Suppl 5):v31-2. PubMed ID: 18784137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group.
    Kowal-Bielecka O; Avouac J; Pittrow D; Huscher D; Behrens F; Denton CP; Foeldvari I; Humbert M; Matucci-Cerinic M; Nash P; Opitz CF; Rubin LJ; Seibold JR; Strand V; Furst DE; Distler O;
    J Rheumatol; 2010 Jan; 37(1):105-15. PubMed ID: 19955042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Existing and novel biomarkers for precision medicine in systemic sclerosis.
    Wermuth PJ; Piera-Velazquez S; Rosenbloom J; Jimenez SA
    Nat Rev Rheumatol; 2018 Jul; 14(7):421-432. PubMed ID: 29789665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frontiers in translational systemic sclerosis research: A focus on the unmet 'cutaneous' clinical needs (Viewpoint).
    Herrick AL; Shukla R; Watson REB
    Exp Dermatol; 2020 Dec; 29(12):1144-1153. PubMed ID: 32840924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.